glp 1 hepatic steatosis Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Current Status of Glucagon-like Peptide-1

Major biopharmaceutical companies, including Novo Nordisk, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Eccogene, AstraZeneca, and others, are driving innovation in the GLP-1 agonists space through robust pipelines, strategic collaborations, and the development of next-generation treatments targeting diabetes, obesity, and related metabolic disorders

For urgent but non-life-threatening concerns, contact NHS 111 or the NHS urgent mental health helpline

Many patients prescribed Ozempic or similar GLP-1 receptor agonist drugs to treat diabetes or support weight management have reported severe and prolonged vomiting, stomach paralysis, intestinal obstruction, and other serious gastrointestinal injuries

Function Category

GliSODin was shown to protect against cellular oxidative stress damage in a dramatic human model